NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india) arrow 11661.05 72.70 0.63%
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Valeant Pharmaceuticals (TSE: VRX)

 
VRX Technical Analysis
4
As on 31st Oct 2017 VRX Share Price closed @ 15.07 and we RECOMMEND Sell for LONG-TERM with Stoploss of 17.90 & Strong Sell for SHORT-TERM with Stoploss of 16.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

VRX Share Price

Open 15.11 Change Price %
High 15.52 1 Day 0.44 3.01
Low 14.70 1 Week 0.00 0.00
Close 15.07 1 Month -1.64 -9.81
Volume 1911897 1 Year -9.35 -38.29
52 Week High 25.38 | 52 Week Low 11.20
 
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
LSG 2.08 8.33%
TBE 0.03 0.00%
ECA 15.09 4.43%
SC 60.83 -0.44%
PRE 0.64 0.00%
ELD 1.62 -6.90%
MFC 25.94 -0.04%
CPG 10.61 4.53%
BBD-B 2.73 -1.09%
 
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
GGA 0.06 20.00%
ANX 0.07 16.67%
ANX 0.07 16.67%
COM 2.27 14.07%
 
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
NXJ 2.35 -10.31%
NXJ 2.35 -10.31%
RN 0.09 -10.00%
RN 0.09 -10.00%
CTU-A 0.19 -9.52%
TNP 0.90 -9.09%
TNP 0.90 -9.09%
TNX 0.34 -8.11%
QEC 0.74 -7.50%
 
 
VRX
Daily Charts
VRX
Intraday Charts
Whats New @
Bazaartrend
VRX
Free Analysis
 
VRX Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE15.83
RESISTANCE15.52
SUPPORT14.62
SUPPORT14.31
SUPPORT0.00
SUPPORT0.00
 
VRX Target for Month July
4th UP TARGET22.72
3rd UP TARGET20.27
2nd UP TARGET18.75
1st UP TARGET17.23
1st DOWN TARGET12.91
2nd DOWN TARGET11.39
3rd DOWN TARGET9.87
4th DOWN TARGET7.42
 
VRX Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
VRX Target for Year 2019
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
VRX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.valeant.com
 
VRX Address
VRX
2150 St. Elz
Laval, QC H7L 4A8
Canada
Phone: 514-744-6792
Fax: 514-744-6272
 
VRX Latest News
 
Your Comments and Response on Valeant Pharmaceuticals
 
VRX Business Profile
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
 
2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service